Background: The identification of reliable markers for diagnosis of breast cancer has been thoroughly addressed by metabolic profiling using nuclear magnetic resonance (NMR) spectroscopy or imaging. Several clear diagnostic indicators have emerged using either in vitro analysis of tissue extracts, ex vivo analysis of biopsies or in vivo direct spectral observations. Most of the breast cancer characteristic metabolites could be assayed by mass spectrometry (MS) to exploit the superior sensitivity of this technique and therefore reduce the traumatic impact of current biopsy procedures. Methods: Following extraction, aqueous metabolite mixtures were obtained that were submitted to liquid-chromatography, electrospray-ionization, mass spectrometry (LC/ESI-MS) analysis to estimate the content of choline (Cho) and its phosphorylated derivatives, phosphocholine (PCho) and glycerophosphocholine (GPCho). The determinations were performed using 10 samples from breast tissue biopsies, surgical specimens and one single sample of a hepatic metastasis. In addition, some measurements were also repeated using highresolution
Introduction
Breast cancer is certainly one of the most important causes of cancer related deaths in women in industrialized countries. According to the most recent data from the American Cancer Society (1), the estimated new diagnoses of in situ and invasive breast cancer in the USA for 2009 is approximately 255,000 cases, with approximately 40,000 expected to die from the disease. The latter figure accounts for approximately 18% of the cancer mortality in women, which is the same level observed in European countries. It is widely recognized that successful treatment of the disease depends partly on early diagnosis. The most widespread methods for preventive screening are palpation, ultrasonography, mammography and, increasingly, magnetic resonance imaging (MRI) (2) . All of the imaging techniques are also routinely applied to help in the diagnosis in conjunction with histological characterization. Despite this, the identification of reliable markers to improve detection and diagnostic sensitivity and specificity, would be an important achievement. Metabolic profiling is extremely relevant to cancer biology because of the substantial metabolic changes in tumors (3) . For many years nuclear magnetic resonance (NMR) spectroscopy was used for this purpose because of several, potentially advantageous, features. Direct observations by 1 H or 31 P NMR on tissue extracts or perfused cells enabled detection of several metabolites that could be correlated with the character, tumor or not, of the source tissue or culture (reviewed in 3, 4) . In spite of this promising approach, the results were not completely satisfactory. In addition, the serious problems from sample heterogeneity and protocol reproducibility, experimental sensitivity limits, absolute quantification difficulties, and sample alteration induced by experimental treatments often led to controversial results. However, from the com- posite and complex endeavour on breast cancer research, diagnosis and therapy, a couple of interesting findings are emerging. These findings will probably set the standard for future diagnostic protocols. First, based on advancements in magnetic resonance techniques and instrumentation, it is now possible to obtain high quality spectra of tissue biopsies using the high-resolution magic-angle spinning (HR-MAS) approach, without submitting the specimens to extraction procedures (5, 6) . In addition, the direct tissue observation by NMR spectroscopy is becoming more and more viable in vivo, rather than ex vivo, by exploiting the spectroscopic capabilities of modern MRI tomographs (2, 4) . Second, tumor metabolic pathway studies have led to the recognition of increased choline kinase activity in mammary cancer cells, hence rationalizing the quantification of phosphocholine and phosphoethanolamine pools and derivatives thereof (7) (8) (9) (10) . Based on these latter findings, the results of Beckonert and associates (11) from 1 H NMR analysis of samples obtained by dual-phase (organic/aqueous) extraction are reassuring. The reliability of the sample treatment protocol and the extent of identified diagnostic metabolites through smart data reduction procedures (11, 12) show very interesting perspectives. This significantly helps improve the effectiveness of marker-based early screening. Further, confidence comes from recent reports that highlight the detection of a few metabolic markers for cancer diagnosis (13) (14) (15) . Along this line we propose to exploit the high sensitivity of modern mass spectrometers for the detection and quantitation of the metabolites that are relevant markers for breast cancer diagnosis. The technique may be a useful complement to NMR analysis. In this first exploratory report we show that the mass spectrometry approach appears to be a viable route for the targeted analysis of biopsy aqueous extracts. This initial step should be extended to establish the specific standards for analytical confidence and to develop mass spectrometric characterization of other relevant metabolites. The procedure could be coupled to further qualitative NMR assessment to establish robust diagnostic protocols.
Materials and methods

Samples
Biological samples were obtained from fine needle biopsy or from surgical excision of breast tissue. A single sample was a biopsy specimen from a hepatic metastasis. The relative histogical classifications were performed independently by the Pathologic Anatomy Department of AOUD. Following collection, every sample was frozen in liquid nitrogen and stored at -808C until the time of analysis, when each sample was quickly weighed and pulverized. The starting amount of wet tissue ranged from 35 to 160 mg. The extraction protocol followed, with minor changes, the procedure previously described by Koc and coworkers (16) . Briefly, the pulverized material was suspended in 0.400 mL methanol/chloroform (2:1 v/v) and, after thorough vortexing, left overnight at -208C. The sample was then centrifuged at 1500 g (r av ;15 cm) for 5 min and the supernatant extract was separated and stored at -208C. The residue was submitted to re-extraction with 0.250 mL of methanol/chloroform/ water (2:1:0.8 by volume) and the supernatants from both extractions combined. The resulting solution was centrifuged for 5 min after the addition of 0.100 mL of water and 0.100 mL of chloroform. The organic and the aqueous phase were easily visualized and could be separated. Only the aqueous phase containing the analytes of interest ( Figure 1 ) was retained. This aqueous phase was directly lyophylized and then redissolved in 20 mL water and 0.800 mL methanol (2.4% H 2 O by volume). The resulting minute amounts of precipitates (proteins) were removed by centrifugation. In a few cases, aliquots of 1 mL extract were used directly for liquid-chromatography electrospray-ionization mass spectrometry (LC/ESI-MS) analysis following a 20-fold dilution. Alternatively, after the last centrifugation, the solution was split into four aliquots that were frozen and stored at -808C. For LC/ESI-MS analysis, each aliquot was diluted to a suitable concentration with water/methanol and a further increase in the organic fraction; the final H 2 O content was 0.5% by volume (samples E, F, G, H and I, Table 1 ). This reduced water content with respect to the former conditions (2.4%) appeared to improve the quality of the chromatographic elution of the analytes.
The metabolite extraction protocol described above was also applied to the samples prepared for NMR analysis, up to solubilization of the lyophylized aqueous phases in methanol/water (97.6/ 2.4 v/v). Following a further centrifugation step to remove possible residual proteins, methanol was evaporated in a Speed-Vac apparatus. The resulting solutions were diluted to a volume of 0.5 mL by addition of D 2 O.
LC/ESI-MS
Analysis by LC/ESI-MS was performed with a Q-STAR mass spectrometer (Applied Biosystems-SCIEX) using the atmospheric pressure electrospray ionization source. The system also included an Agilent 1100 series micro LC pump. The stationary phase for the separation was a HILIC TSK-Gel Amide-80 column (150 mm=50 mm ALLTECH GROM). A 60-min gradient program was performed starting at 90% and decreasing to 10% of solvent mixture B in 35 min (from the 5th to 40th min of the run). Alternatively, a slower gradient program was selected, with solvent mixture B decreasing from 90% to 10% in 65 min (starting from minute 0 of the run). This slower gradient protocol was applied only to the sample aliquots of the E-I series that did not undergo further dilution to decrease the final H 2 O content. However, the final results were all obtained using the faster chromatographic protocol. The errors for the analyte ratios were calculated using standard error propagation. The experimental uncertainties on the analyte contents were estimated from the spread obtained by using different calibration curves for samples A, B, C, D and J. For samples E, F, G, H, I, the experimental uncertainties were estimated from Eq. w1x (materials and methods).
system through a Rheodyne model 8125 valve using either a 5-or 20-mL completely filled loop, and the flow was set at 5-10 mL/min.
Electrospray mass spectra were recorded in the positive ion mode by exploiting, essentially in the preliminary setup phase, the features of the acquisition software to duplicate the number of transmission windows when applying the alternating declustering potential (ADEPO) approach, as previously described (17) . Data were analyzed using Applied Biosystems-SCIEX Analyst QS software (1.0 version) with the Analyst Calculator Tool.
NMR
The methanol free metabolite solutions adjusted to 0. H NMR experiments were acquired with a Bruker Avance spectrometer operating at 500 MHz. Using a sweep width of 8 kHz, 8-16 K complex data points were collected to average 1024-8000 transients. A relaxation delay of 5 s, along with 308 flip-angle pulses, were used. Presaturation was used for suppression of the HOD signal during the whole relaxation delay. A Gaussian window multiplication of the FID was applied to enhance resolution of partially overlapping peaks. Residual overlap of the signals of interest was treated using the deconvolution routine of the Bruker TOPSPIN software by fitting a mixed Lorentzian/Gaussian lineshape to the experimental envelope.
Data treatment
The experimental analyte peaks from LC/ESI-MS were evaluated by integrating the respective extracted ion chromatograms (XICs) using the analysis software ( Figure 1 ). The total analyte content in the samples undergoing mass spectrometry determinations were different. With the initial protocol that used 2.4% H 2 O content in the final solution, smaller overall amounts of analytes were submitted to measurement with respect to the corresponding amounts analyzed in solution with 0.5% H 2 O content. However, we were not interested in the absolute metabolite content, but rather in their ratios. All experimental determinations were repeated at least twice and satisfactory reproducibility was generally observed. The reproducibility of the determinations was always within 20%. Calculation of an inter-assay coefficient of variation for the estimation of single metabolites did not seem appropriate because the level of each metabolite under consideration is variable between individuals, even being independent of the presence of pathology. Besides the critical reproducibility of the initial pulverization step, which essentially affected the absolute metabolite quantitations, the largest source of error was due to the uncertainty of the calibration curves. For each analyte of interest in fact, we built calibration curves (see Supplemental data, Figure 1 ) with standard controls to establish a correspondence between the measured XIC counts and the absolute concentration calculated thereof. In order to improve the reliability of the calibrations, the standard solutions were prepared as mixtures of choline (Cho), phosphocholine (PCho) and glycerophosphocholine (GPCho) at known concentrations, with the same solvent mixture compositions that were employed for real samples. However, quantitative estimation from different mass spectrometry experiments remains critical. In general, the calibrations relying on the correspondence between the XIC value and the absolute concentration should be performed with the same set of experimental conditions as the actual measurements. It is expected that the use of suitably labelled isotopomers of the analytes of interest as internal concentration standards should avoid specific experimental drift, as well as time-consuming calibration procedures for each specific set of operation conditions, and thus should be preferred for either absolute or relative quantification (16) . For the data presented here, the error for each determined concentration, s x0 , was estimated from calibration curves using the formula:
where s y/x is the standard deviation of the ordinate residuals of the linear calibration curve, b is the slope of the same curve, y 0 is the specific experimental XIC area value, y av , x av and x i are, respectively, the average values and the actual values of the experimental points used to obtain the calibration curve. For the data obtained with the initial protocol, no specific calibration was available and therefore the error assessment relied on the spread obtained from different calibration curve determinations. The concentration errors were combined using standard error propagation to calculate the reported ratio uncertainties. (Table 1 , sample I). Cho (blue traces), PCho (orange traces), GPCho (green traces). The Cho (blue trace) and PCho (orange trace) components that occur at the same retention time as GPCho are due to in-source fragmentation of the latter metabolite. All mass spectra were obtained using a DP value of 40 V. In this condition, GPCho undergoes a double in-source neutral-loss transformation, the first by hydroxy-acetone loss (CH 2 OH-CO-CH 3 , the ketone form of dehydro-glycerol) leading to PCho, and then by HPO 3 loss leading to Cho. The characterization of these fragmentation patterns was accomplished by preliminary tests on model compounds (17) . The peak at 7-10 min of retention time (blue trace) is an unidentified, chromatographically-resolved species with the same molecular weight as choline (with a tolerance of 0.1 Da).
Results
Protocol setup
The setup of the LC/MS method for the separation and the identification of relevant metabolites in breast cancer tissue was achieved in two steps. First, the mass spectra of analyte standards were acquired and interpreted to check the specific ionization paths, charge states, possible in-source or postsource fragmentation processes, etc. The selected analytes were: betain, Cho, PCho, GPCho and acetylcholine ( Figure  1 ). The mass spectrum acquisition parameters were individually tuned to optimize ionization and transfer to quadrupole analyzer. The identification of the analytes took advantage from control of both focusing (FP) and declustering (DP) potentials. The latter parameter proved quite critical to control the integrity of the ionised species because of the chemical lability of the mentioned metabolites. In particular, with DP values ranging between 40 and 130 V, the analytes underwent specific degradation pathways; ideally suited for unequivocal identification of the precursor ion species. The procedure is equivalent to the ADEPO method proposed for the identification of protein phosphorylation sites (17) .
The second phase entailed searching for the optimal conditions for chromatographic resolution of the tissue extracts. All attempts to achieve separation using reverse phase chromatography, i.e., non-polar stationary phase (plain or partly polar-functionalised C18 columns) and a decreasing polar mobile phase, were unsuccessful. Instead, separation was obtained with hydrophilic interaction stationary phases (HILIC Amide-80 columns) and increasing polar mobile phases. The analytes were eluted from the stationary phase within time intervals ranging from about 3-10 min (acetylcholine) to 20-40 min (PCho), depending on the chosen polarity gradient.
LC/ESI-MS analytical pattern
Following the initial setup phase, a reliable protocol could be established for sample treatment, analyte extraction and LC/ESI-MS assessment. The details have been described in materials and methods. The procedure was applied to the analysis of seven mammary fine-needle biopsies that were obtained from patients with suspected breast cancer, two surgical specimens of mammary tissue from healthy individuals undergoing cosmetic breast surgery, and a single-surgical specimen of hepatic metastasis. The results are reported in Table 1 ; examples of extracted ion current chromatograms (XICs) are shown in Figure 2 . At first glance, the ratio of phosphorylated choline metabolites to the unphosphorylated precursor appears to be increased in tumor lesions compared to healthy or fibrocystic tissues. This increase occurs in both malignant and benign tumors, as seen with malignant carcinoma and borderline sclerosing (scleroelastotic) nodule samples compared with the two fibroadenoma samples. The possibility for obtaining false-positives with fibroadenoma lesions is known to affect 1 H NMR-based diagnosis (2), and also reported in an early investigation on fine-needle biopsy specimens (18) . Also, the data in Table 1 indicates that the other reported ratio, including GPCho, does not enable clear discrimination of malignancy. The total phosphorylated/ unphosphorylated choline metabolite ratio increases less significantly with respect to the PCho/Cho ratio in any of the analyzed cases of neoplastic occurrence. As discussed in material and methods, absolute metabolite quantitation initially obtained using the ESI-MS calibration curves was not very satisfactory. The amounts of metabolites that could be measured were dependent, most essentially, on the efficiency of the initial pulverization step, as well as the water content of the solution submitted to mass spectrometry, which affected the shape of the chromatographic peaks. Therefore, the subsequent NMR controls used to validate the LC/MS procedure provided also reliable and independent measurements of the metabolite concentrations in the breast tissue samples that were analyzed. The absolute quantitation uncertainties proved significantly reduced with the hepatic metastasis sample. This was likely because of the effect of the tissue homogeneity which improved the recovery efficiency of the assayed metabolites. For Cho, PCho and GPCho, we estimated contents of 0.35"0.05, 3.0"0.45 and 0.55"0.06 nmol/mg of wet tissue, respectively. These values appear consistent with the previously reported concentration ranges obtained by 31 P NMR measurements (3, 19) . The recovery levels achieved with the fine-needle biopsy samples were typically reduced by one order of magnitude compared with the hepatic metastasis.
NMR analytical pattern
The aqueous extract solutions from healthy breast tissue (four specimens from two individuals) were characterized by 1 H NMR spectroscopy to validate the proposed LC-ESI-MS protocol, and to evaluate the choline metabolite content when assessed by mass spectrometry. With amounts of tissue larger than those available from fine-needle biopsies, extraction could ensure proper concentrations for NMR measurement viability. A typical spectrum is shown in Figure 3 , and the complexity of the pattern is immediately evident. The assignments of most of the signals have been reported (6) , but for our purposes, only the region between 3.15 and 3.30 ppm was taken into consideration because of the presence of the N-trimethyl peaks due to choline and its derivatives (6, 20) . Unfortunately, the advantages of the singlet multiplicity of the N-trimethyl signals, ideally suited for quantitation, are neutralized by the occurrence, in the same region, of other resonances, such as the C 2 H of b-glucose or the N-CH 2 's of taurine, phosphoethanolamine (PE) and glycerophosphoethanolamine (GPE), and the N-trimethyl of acetylcholine and betaine (6, 20) . This results in signal crowding and substantial overlap, with further complications arising from small chemical shift changes that depend on the conditions and history of each sample. As a matter of fact, proper resolution of the resonances enabling accurate estimate of the individual choline metabolites is seldom obtained and, especially when 1 H spectra are acquired in vivo by MRI tomographs, the overall cumulative integral of the N-trimethyl resonances is considered and referred to as the 'Choline peak'. The high resolution spectrum of Figure 3 exhibits a well-resolved Cho peak at 3.205 ppm, followed by an envelope of at least three signals that encloses GPCho (3.232 ppm) and PCho (3.228 ppm), along with an upfield component that could arise from PE (6, 20) . For the other examined samples, the situation was similar or even worse. Hence, a safe concentration estimate could be obtained only for the Cho signal. In the most favorable case, deconvolution of the envelope Cho, PCho and GPCho content determined by additional lineshape fitting of the envelope including the phosphorylated choline derivatives. Errors were always evaluated from the uncertainty (10%) affecting the NMR peak amplitudes that were obtained from lineshape fitting.
was also attempted for the other two choline derivatives to evaluate their cumulative concentration (Table 2 ). In any case, line fitting of the Cho signal, as well as of the CH 2 Cl 2 peak added as internal reference, was performed and the areas were used to estimate the concentration of the metabolite in the different specimens. The corresponding absolute Cho contents per mg of wet tissue sample, reported in Table 2 , are consistent with the data reported in the literature (3, 21) , thus confirming the validity of the extraction protocol. However, the value obtained for the quantitation of the pool of choline phosphorylated derivatives (Table 2) deviates from the corresponding pool measured by LC/ESI-MS. Beyond the limited statistical significance of a single specimen determination with respect to comparison between NMR and mass spectrometry, it should be noted that a low-value of the (PChoqGPCho)/Cho ratio for healthy tissue is also confirmed by NMR.
Discussion
The main aim of the presented work was the development of a suitable mass-spectrometry-based protocol for quantification of the relative amounts of choline and phosphoderivatives in breast cancer tissues. In fact, compared to NMR, mass spectrometry analysis is much more sensitive, and thus expected to cope better with the small amounts of tissue specimens that are commonly available from fine-needle biopsies, and which are not typically suited for NMR analysis. For our determinations, the employed sample amounts for mass spectrometry were at least three orders of magnitude below the typical load for NMR extracts. Therefore, if properly standardized, assessment using mass spectrometry may, in principle, be employed in biopsy protocols which are significantly less invasive than fine-needle aspiration; i.e., for tissue samples of a few hundred micrograms or less. The results shown in Table 1 prove quite encouraging. Following a successful extraction step, the subsequent LC/ESI-MS analysis always revealed an unambiguous increase in the phosphorylated-to-unphosphorylated ratio of the choline metabolites in breast tumor tissues, either malignant and benign, compared to healthy or fibrocystic counterparts. The same high ratios were also confirmed in a hepatic metastasis. This result is fully consistent with the vast body of evidence reported in the literature (2) (3) (4) (5) (8) (9) (10) (11) (12) (13) (14) (15) . No specific malignancy discrimination was shown by any of the considered metabolite ratios (Table 1 ), a conclusion that can also be extended to the PCho/GPCho ratio held to increase systematically in malignant lesions (3). We did not report this last parameter because it coarsely exhibited the same trend as the other two ratios that were considered, i.e., PCho/Cho and (PChoqGPCho)/Cho. A substantial difference was seen for the sclerosing nodule (Biopsy E in Table 1 ), a borderline lesion that showed a PCho/GPCho ratio -2 and which was similar to all of the analyzed non-tumor specimens. Of interest, while the malignant cancer biopsies had a PCho/GPCho ratio between 5.5"1.4 (hepatic carcinoma metastasis) and 55"15 (ductal carcinoma), the benign fibroadenomas exhibited higher values (75"19 and 122"31) for the same parameter. However, a larger number of specimens, also including healthy tissue controls from the same individuals, would be needed to establish the statistical relevance of this difference that would enable one to distinguish benign from malignant tumor tissues.
Since the primary aim of our investigation was to estimate, by mass spectrometry, the breast tissue choline content relative to phosphocholine derivatives, a standard extraction protocol (16) was used initially, and no optimization of metabolite recovery was attempted. As a matter of fact, the absolute quantitation gave considerably lower values compared to the reported physiological levels, except for a single sample of hepatic metastasis (sample J in Table 1 , see results). Subsequently, the extraction protocol was repeated on the two healthy subject surgical specimens (samples H and I of Table 1 ) which were still available. With careful treatment for metabolite retrieval, the larger amounts of material enabled collecting extracts suitable for NMR analysis that provided quantitative results in agreement with previously reported data. Successful absolute quantitation was achieved when the processed samples were fairly homogeneous, as with the hepatic metastasis, or large enough to balance the typical inhomogeneity of the breast tissue, as seen with the surgical specimens. In fact, the very first pulverization of the frozen wet material proved to be the most difficult and crucial step of the procedure, and quite likely the principal source of error for absolute quantification of metabolite. Especially very limited sample amounts, suitable only for mass spectrometry, are expected to exhibit problematic absolute quantitation. However, this drawback should not impair the analytical result as long as valuable diagnostic responses may well rely only on the relative content of specific markers.
The LC/ESI-MS methodology described here is essentially ill suited for in vitro absolute quantitative estimates, unless isotopically-labeled analytes are added as internal reference. However, besides the much higher sensitivity, it shows several other advantages compared to in vitro NMR spectroscopy analysis, In fact, for breast tissue metabonomics, the choline metabolites Cho, PCho and GPCho are well-resolved on the molecular mass scale, as are other important tumor markers, such as PE and GPE, taurine and lactate (3, 4, 11, 12) , whose observation would require properly optimized extraction protocols and specific switching of the mass spectrometer to negative ion detection mode. NMR spectroscopy is certainly more versatile than mass spectrometry because all of the mentioned metabolites can be observed at once in aqueous extracts, and most of them either in a 1 H spectrum or, with a much lower sensitivity, in a 31 P spectrum. Unfortunately, complete resolution of the individual component signals is seldom achieved at any nuclear frequency, even using fairly high (14 T) magnetic fields (6, 12) . Hence, NMR quantitation of the individual metabolite contents should be obtained by post-processing manipulation of the spectroscopic data by deconvolution (20) . In general, attempting to overcome the poor spectral resolution by applying deconvolution routines is difficult due to the inherent complexity of the extract spectra, and the broad variability of many metabolite concentrations. Even by restricting the analysis to limited spectral regions, such as that of the choline metabolite N-trimethyl signals, resonance crowding may remain a major problem, as shown in Figure 3 . In addition, possible slight magnetic field inhomogeneities may always occur and thus affect the lineshape-fitting analysis, thereby increasing the number of assumptions and parameters necessary for the fitting. Some remedies have been specifically proposed for choline derivative assessment based on spectral editing through heteronuclear 31 P INEPT experiments (22) . This clever manipulation, enabling one to single out the phosphoester CH 2 resonance of PCho and GPCho, would not necessarily lead to isolated methylene signals due to possible overlapping interference of analogous groups from PE and GPE, or other phosphorylated metabolites, such as phosphocreatine, without mentioning the sensitivity penalty incurred by heteronuclear editing. Although possible selective excitation schemes for 31 P INEPT experiments may overcome the above resolution problems, both sensitivity and resolution requirements could be tackled by selective 1 H experiments processed by Singular Value Decomposition (23) . However, all of these approaches are expected to largely fail when the raw NMR signal has an inherently lower resolution, as with ex-vivo specimens analyzed by HR-MAS (5, 6). Indeed, for in vivo direct detection, the only reasonably viable evidence for metabonomics analysis rests on the N-trimethyl envelope of the so-called 'Choline peak' that may enclose several marker metabolites. With ex-vivo and in-vivo data, sophisticated processing procedures other than the conventional Fourier transform (24, 25) could probably be successfully implemented when sufficient experimental sensitivity can be routinely achieved.
Both sensitivity and resolution issues are instead properly addressed by the mass spectrometry approach that has been presented, whereas absolute quantitative results from the LC/ ESI-MS methodology could prove less feasible, especially for simultaneous estimates of labile compounds that may undergo modification during the ionization step. These problems may be circumvented by proper isotopic dilution schemes (16) designed to reproduce, and hence account for the differential extent of individual analyte recovery during the whole analysis cycle. Along with possible metabolite retrieval difficulties in the extraction steps, the major difficulty of a mass-spectrometry-based approach to the search of breast cancer markers is the necessity for setting up a specifically suited protocol for each analyte, or group of analytes, by optimizing first the extraction procedures, followed by the chromatographic separation, and finally by the ionization, detection and quantitation steps for the mass analysis. The mass analysis problems may be of particular relevance if the determinations are extended also to the organic phase extracts that should exhibit a inherently complex phospholipid metabolite profile. Mass spectrometry analysis should be performed using proper approaches, such as multiple reaction monitoring (26) ; i.e., a multiplex version of the selected reaction monitoring method. Since an exhaustive analytical protocol relying only on LC/MS could be quite complex and time demanding, the perspective of an extensive or exclusive LC/MS involvement in diagnostic breast tissue metabonomics and other similar tasks, should be considered with some caution, in spite of appealing cutting-edge applications, such as mass spectrometry imaging (27) . Instead, complementary and flexible usage of LC/MS and NMR would ensure the routine exploitation of both sensitivity and resolution advantages of the former technique, together with the versatility of the latter. Some interesting applications along these guidelines have already been described (28, 29) .
Our results successfully show that, for breast cancer metabonomics, a protocol based on the complementary application of LC/MS and NMR is definitely viable and is already the current state of the art. Further studies may only improve the robustness of this combined approach.
